Bedrosian Camille L sold (to issuer) $1.9M of CRNX
Bedrosian Camille L sold (to issuer) 22,225 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($1.89M total) across 2 trades on 2026-09-01.
How this was made
The 30-second read
Why it matters
The sale reduces insider ownership to zero, which may be interpreted as a negative signal but lacks material weight.
Market read
Insider sell is a routine disclosure with limited trading relevance.
What to watch
Potential upcoming financing or dilution events not disclosed in the filing.
Background
Form 4 filings disclose insider transactions; this is the first public report of the sale.
Ticker impact
Director Camille Bedrosian sold 22,225 shares for $1.889M, reducing her stake to zero.
Potential short-term pressure; limited upside impact.
Director sales are routine; $1.9M is not material for a mid‑cap biotech, but zero holdings could be noted by traders.
Market effects
Minimal effect on biotech sector; insider activity is routine.
None
None
Counterpoint
Sale could be unrelated to company outlook; may present a buying opportunity if fundamentals remain strong.
Key entities
- CompanyCrinetics Pharmaceuticals, Inc.
Biopharma listed on NASDAQ under CRNX.
- DirectorCamille L. Bedrosian
Director of Crinetics who sold her entire shareholding.
